Current evidence on the discontinuation of eculizumab in patients with atypical haemolytic uraemic syndrome

@inproceedings{Maci2017CurrentEO,
  title={Current evidence on the discontinuation of eculizumab in patients with atypical haemolytic uraemic syndrome},
  author={M. Dolors Maci{\`a} and Fernando de {\'A}lvaro Moreno and Tina Dutt and Ingela Fehrman and Karine Hadaya and Christoph Gasteyger and Nils Heyne},
  booktitle={Clinical kidney journal},
  year={2017}
}
Background. Atypical haemolytic uraemic syndrome (aHUS) is a rare, life-threatening disorder for which eculizumab is the only approved treatment. Life-long treatment is indicated; however, eculizumab discontinuation has been reported. Methods. Unpublished authors' cases and published cases of eculizumab discontinuation are reviewed. We also report eculizumab discontinuation data from five clinical trials, plus long-term extensions and the global aHUS Registry. Results. Of six unpublished… CONTINUE READING

References

Publications referenced by this paper.
Showing 1-10 of 53 references

Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype.

Clinical journal of the American Society of Nephrology : CJASN • 2010
View 4 Excerpts
Highly Influenced

Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome.

The New England journal of medicine • 2013
View 5 Excerpts
Highly Influenced

Atypical aHUS: State of the art.

Molecular immunology • 2015
View 1 Excerpt

Similar Papers

Loading similar papers…